About
About us
Leadership
Investors
Pipeline
Pipeline
OncoMimics™
Platform
Our Mimicry Approach
Our Drug Discovery Platform
Clinical Trials
B cell malignancies
Glioblastoma
Adrenal tumors
Colorectal Cancer
News & Events
Press Releases
Press Coverage
Webinars
Presentations & Posters
Relevant Literature
Careers
Our Values
Careers
EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study
2023 SNO Annual Meeting
Enterome
Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel:
+33 (0)1 75 77 27 85
Email:
info@enterome.com
Metro Station: Ledru-Rollin (Line 8)
